Franco Folli

Milan, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 122 publications

The interaction between glucose levels and body mass index on the regulation of the circulating sphingolipidome in humans.

The interaction between glucose levels and body mass index on the regulation of the circulating sphingolipidome in humans.

Journal: American journal of physiology. Endocrinology and metabolism

Published: March 24, 2026

Depression severity and efficacy outcomes: post hoc analyses from a phase 3 trial of esmethadone for the adjunctive treatment of major depressive disorder with inadequate response to standard antidepressants.

Depression severity and efficacy outcomes: post hoc analyses from a phase 3 trial of esmethadone for the adjunctive treatment of major depressive disorder with inadequate response to standard antidepressants.

Journal: International clinical psychopharmacology

Published: February 27, 2026

Letter to the Editor on "GLP-1 receptor agonists and coronary plaques regression in diabetic patients after acute coronary syndromes".

Letter to the Editor on "GLP-1 receptor agonists and coronary plaques regression in diabetic patients after acute coronary syndromes".

Journal: Acta diabetologica

Published: January 22, 2026

Synergic effect of diet and polysaccharide-based complex administration in the treatment of children and adolescents with metabolically unhealthy obesity: the Polymets Study.

Synergic effect of diet and polysaccharide-based complex administration in the treatment of children and adolescents with metabolically unhealthy obesity: the Polymets Study.

Journal: Journal of endocrinological investigation

Published: December 02, 2025

Low, non-psychedelic doses of psilocybin as a novel treatment for MASLD, obesity and type 2 diabetes via 5-HT2B receptor-dependent mechanisms.

Low, non-psychedelic doses of psilocybin as a novel treatment for MASLD, obesity and type 2 diabetes via 5-HT2B receptor-dependent mechanisms.

Journal: Pharmacological research

Published: October 30, 2025

Esmethadone (REL-1017) in Patients With Major Depressive Disorder and Antidepressant Tachyphylaxis: An Exploratory Post Hoc Analysis From a Phase 3 Randomized Controlled Trial.

Esmethadone (REL-1017) in Patients With Major Depressive Disorder and Antidepressant Tachyphylaxis: An Exploratory Post Hoc Analysis From a Phase 3 Randomized Controlled Trial.

Journal: The Journal of clinical psychiatry

Published: October 08, 2025

Analysis of morbid obese diabetic and non-diabetic patients: clinical and social characteristics, habits and workup to undergo bariatric surgery in Lombardy, Italy.

Analysis of morbid obese diabetic and non-diabetic patients: clinical and social characteristics, habits and workup to undergo bariatric surgery in Lombardy, Italy.

Journal: Acta diabetologica

Published: September 09, 2025

Lipidome profile of cystic fibrosis-related diabetes, type 1 and type 2 diabetes mellitus: potential links to inflammation and glucose and lipid metabolism.

Lipidome profile of cystic fibrosis-related diabetes, type 1 and type 2 diabetes mellitus: potential links to inflammation and glucose and lipid metabolism.

Journal: American journal of physiology. Endocrinology and metabolism

Published: August 29, 2025

Continuous interstitial glucose monitoring in diabetic and non-diabetic critically ill patients is simple and accurate: comparison with venous, arterial and capillary glucose measurements.

Continuous interstitial glucose monitoring in diabetic and non-diabetic critically ill patients is simple and accurate: comparison with venous, arterial and capillary glucose measurements.

Journal: Acta diabetologica

Published: March 28, 2025

Long-Term Safety and Efficacy of Esmethadone in Patients With Major Depressive Disorder: Findings From a 12-Month Open-Label Study.

Long-Term Safety and Efficacy of Esmethadone in Patients With Major Depressive Disorder: Findings From a 12-Month Open-Label Study.

Journal: The Journal of clinical psychiatry

Published: February 25, 2025

Reply to the letter comment of Su Boon Yong MD, PhD and colleagues to: Improved glycemic and weight control with Dulaglutide addition in SGLT2 inhibitor treated obese type 2 diabetic patients at high cardiovascular risk in a real-world setting. The AWARE- 2 study.

Reply to the letter comment of Su Boon Yong MD, PhD and colleagues to: Improved glycemic and weight control with Dulaglutide addition in SGLT2 inhibitor treated obese type 2 diabetic patients at high cardiovascular risk in a real-world setting. The AWARE- 2 study.

Journal: Pharmacological research

Published: January 30, 2025

Improved glycemic and weight control with Dulaglutide addition in SGLT2 inhibitor treated obese type 2 diabetic patients at high cardiovascular risk in a real-world setting. The AWARE-2 study.

Improved glycemic and weight control with Dulaglutide addition in SGLT2 inhibitor treated obese type 2 diabetic patients at high cardiovascular risk in a real-world setting. The AWARE-2 study.

Journal: Pharmacological research

Published: October 22, 2024

Showing 1-12 of 122

Last Updated: 09/26/2026